RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -1.4 Million USD | -5.54% |
| 2021 | -1.27 Million USD | -2.91% |
| 2020 | -1.29 Million USD | -3.31% |
| 2019 | -1.24 Million USD | 34.36% |
| 2018 | -1.9 Million USD | -32.04% |
| 2017 | -1.44 Million USD | 13.71% |
| 2016 | -1.67 Million USD | 2.07% |
| 2015 | -5.09 Million USD | -10.03% |
| 2014 | -1.55 Million USD | -70.53% |
| 2013 | -565.4 Thousand USD | -9.06% |
| 2012 | -833.73 Thousand USD | 86.11% |
| 2011 | -5.99 Million USD | -19.51% |
| 2010 | -5.02 Million USD | 22.61% |
| 2009 | -6.47 Million USD | 39.73% |
| 2008 | -10.78 Million USD | 8.93% |
| 2007 | -11.15 Million USD | -34.79% |
| 2006 | -8.24 Million USD | -55.14% |
| 2005 | -5.43 Million USD | -69.35% |
| 2004 | -3.32 Million USD | -106.04% |
| 2003 | -1.62 Million USD | -11.55% |
| 2002 | -1.45 Million USD | -110.15% |
| 2001 | -691.24 Thousand USD | 40.77% |
| 2000 | -1.16 Million USD | -500.65% |
| 1999 | 291.29 Thousand USD | 112.71% |
| 1998 | -588.52 Thousand USD | -252.12% |
| 1997 | -649.93 Thousand USD | 52.71% |
| 1996 | -1.4 Million USD | 69.75% |
| 1995 | -4.4 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -304.9 Thousand USD | 1.27% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | - USD | -5.54% |
| 2022 Q1 | -343.76 Thousand USD | 6.46% |
| 2022 Q2 | -464.78 Thousand USD | -35.2% |
| 2022 Q3 | -284.42 Thousand USD | 38.81% |
| 2022 Q4 | -308.82 Thousand USD | -8.58% |
| 2021 Q2 | -257.44 Thousand USD | 14.01% |
| 2021 Q3 | -403.93 Thousand USD | -56.9% |
| 2021 FY | - USD | -2.91% |
| 2021 Q4 | -367.5 Thousand USD | 9.02% |
| 2021 Q1 | -299.39 Thousand USD | -3.0% |
| 2020 Q4 | -290.66 Thousand USD | -3.66% |
| 2020 FY | - USD | -3.31% |
| 2020 Q1 | -335.11 Thousand USD | -12.74% |
| 2020 Q2 | -384.54 Thousand USD | -14.75% |
| 2020 Q3 | -280.41 Thousand USD | 27.08% |
| 2019 Q3 | -272.56 Thousand USD | 19.77% |
| 2019 Q2 | -339.74 Thousand USD | -8.18% |
| 2019 Q1 | -314.05 Thousand USD | -21.18% |
| 2019 FY | - USD | 34.36% |
| 2019 Q4 | -297.25 Thousand USD | -9.06% |
| 2018 Q2 | -341.44 Thousand USD | 63.92% |
| 2018 Q3 | -356.64 Thousand USD | -4.45% |
| 2018 Q4 | -259.15 Thousand USD | 27.33% |
| 2018 FY | - USD | -32.04% |
| 2018 Q1 | -946.28 Thousand USD | -204.3% |
| 2017 Q4 | -310.97 Thousand USD | 29.55% |
| 2017 Q3 | -441.42 Thousand USD | -46.04% |
| 2017 FY | - USD | 13.71% |
| 2017 Q1 | -386.91 Thousand USD | -12.3% |
| 2017 Q2 | -302.26 Thousand USD | 21.88% |
| 2016 Q3 | -377.74 Thousand USD | 23.97% |
| 2016 Q4 | -344.54 Thousand USD | 8.79% |
| 2016 Q1 | -451.59 Thousand USD | -18.17% |
| 2016 FY | - USD | 2.07% |
| 2016 Q2 | -496.81 Thousand USD | -10.02% |
| 2015 FY | - USD | -10.03% |
| 2015 Q4 | -382.15 Thousand USD | 0.52% |
| 2015 Q1 | -389.98 Thousand USD | -5.27% |
| 2015 Q3 | -384.14 Thousand USD | 30.12% |
| 2015 Q2 | -549.74 Thousand USD | -40.97% |
| 2014 Q1 | -362.63 Thousand USD | -608.46% |
| 2014 Q2 | -405.08 Thousand USD | -11.71% |
| 2014 Q4 | -370.47 Thousand USD | 10.14% |
| 2014 FY | - USD | -70.53% |
| 2014 Q3 | -412.3 Thousand USD | -1.78% |
| 2013 Q3 | -251.44 Thousand USD | -2.56% |
| 2013 Q2 | -245.16 Thousand USD | 24.32% |
| 2013 Q1 | -323.93 Thousand USD | -258.48% |
| 2013 FY | - USD | -9.06% |
| 2013 Q4 | -51.18 Thousand USD | 79.64% |
| 2012 Q2 | -223.8 Thousand USD | 47.58% |
| 2012 Q3 | -92.61 Thousand USD | 58.62% |
| 2012 Q4 | -90.36 Thousand USD | 2.43% |
| 2012 FY | - USD | 86.11% |
| 2012 Q1 | -426.94 Thousand USD | 50.44% |
| 2011 Q2 | -1.53 Million USD | 4.04% |
| 2011 FY | - USD | -19.51% |
| 2011 Q4 | -861.46 Thousand USD | 57.26% |
| 2011 Q3 | -2.01 Million USD | -31.7% |
| 2011 Q1 | -1.59 Million USD | -73.54% |
| 2010 Q1 | -1.14 Million USD | 10.29% |
| 2010 Q2 | -1.37 Million USD | -19.63% |
| 2010 Q3 | -1.58 Million USD | -15.92% |
| 2010 FY | - USD | 22.61% |
| 2010 Q4 | -919.01 Thousand USD | 42.13% |
| 2009 Q3 | -1.23 Million USD | 15.07% |
| 2009 Q4 | -1.27 Million USD | -3.08% |
| 2009 FY | - USD | 39.73% |
| 2009 Q2 | -1.45 Million USD | 42.06% |
| 2009 Q1 | -2.51 Million USD | 10.05% |
| 2008 Q3 | -2.39 Million USD | 17.21% |
| 2008 Q4 | -2.79 Million USD | -16.61% |
| 2008 FY | - USD | 8.93% |
| 2008 Q2 | -2.89 Million USD | -8.46% |
| 2008 Q1 | -2.67 Million USD | 27.05% |
| 2007 Q2 | -2.72 Million USD | 15.07% |
| 2007 Q4 | -3.66 Million USD | -64.42% |
| 2007 FY | - USD | -34.79% |
| 2007 Q1 | -3.2 Million USD | -89.24% |
| 2007 Q3 | -2.22 Million USD | 18.25% |
| 2006 Q1 | -1.41 Million USD | 37.61% |
| 2006 Q2 | -354.5 Thousand USD | 75.0% |
| 2006 FY | - USD | -55.14% |
| 2006 Q3 | -2.07 Million USD | -484.32% |
| 2006 Q4 | -1.69 Million USD | 18.16% |
| 2005 Q4 | -2.27 Million USD | -56.73% |
| 2005 FY | - USD | -69.35% |
| 2005 Q1 | -922.43 Thousand USD | -11.03% |
| 2005 Q2 | -1 Million USD | -9.36% |
| 2005 Q3 | -1.45 Million USD | -43.75% |
| 2004 Q4 | -830.8 Thousand USD | 15.45% |
| 2004 Q2 | -363.37 Thousand USD | 68.72% |
| 2004 Q1 | -1.16 Million USD | -127.21% |
| 2004 FY | - USD | -106.04% |
| 2004 Q3 | -982.57 Thousand USD | -170.41% |
| 2003 Q3 | -390.56 Thousand USD | -0.11% |
| 2003 FY | - USD | -11.55% |
| 2003 Q2 | -390.13 Thousand USD | -35.08% |
| 2003 Q1 | -288.82 Thousand USD | 38.57% |
| 2003 Q4 | -511.32 Thousand USD | -30.92% |
| 2002 Q1 | -135.71 Thousand USD | -16.95% |
| 2002 Q3 | -346.46 Thousand USD | 29.85% |
| 2002 FY | - USD | -110.15% |
| 2002 Q2 | -490.06 Thousand USD | -248.4% |
| 2002 Q4 | -469.74 Thousand USD | -35.67% |
| 2001 Q1 | -141.19 Thousand USD | 63.59% |
| 2001 FY | - USD | 40.77% |
| 2001 Q4 | -115.25 Thousand USD | 3.23% |
| 2001 Q3 | -117.29 Thousand USD | 1.12% |
| 2001 Q2 | -120.72 Thousand USD | 60.15% |
| 2000 FY | - USD | -500.65% |
| 2000 Q1 | -112.48 Thousand USD | -137.67% |
| 2000 Q2 | -81.26 Thousand USD | 27.76% |
| 2000 Q3 | -98.1 Thousand USD | -23.18% |
| 2000 Q4 | -170.84 Thousand USD | -772.35% |
| 1999 Q1 | -7206.00 USD | 0.0% |
| 1999 Q2 | -389.00 USD | 94.6% |
| 1999 Q3 | -389.00 USD | 0.0% |
| 1999 Q4 | 298.58 Thousand USD | 76857.84% |
| 1999 FY | - USD | 112.71% |
| 1998 FY | - USD | -252.12% |
| 1997 FY | - USD | 52.71% |
| 1996 FY | - USD | 69.75% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.027% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 76.356% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.814% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 91.93% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.491% |
| Mesoblast Limited | -62.38 Million USD | 97.753% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 8.739% |
| Genus plc | 73.7 Million USD | 101.902% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 78.797% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 60.479% |
| Marizyme, Inc. | -34.28 Million USD | 95.911% |
| ContraFect Corporation | -64.99 Million USD | 97.843% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 84.02% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 69.029% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 46.991% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 39.677% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -170.595% |
| Accustem Sciences Inc. | -3.74 Million USD | 62.583% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.093% |
| EV Biologics, Inc. | -1.26 Million USD | -10.628% |
| Q BioMed Inc. | -617.62 Thousand USD | -126.966% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 139.244% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -121.663% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 38.638% |
| Biomind Labs Inc. | -1.03 Million USD | -35.499% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 114.193% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 80.425% |
| Skye Bioscience, Inc. | -13.54 Million USD | 89.653% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 5.755% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -5507.232% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 63.911% |
| IMV Inc. | -35.52 Million USD | 96.054% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.167% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 43.972% |
| GB Sciences, Inc. | -1.41 Million USD | 1.273% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.557% |
| HST Global, Inc. | -5303.00 USD | -26334.245% |
| CSL Limited | 4.78 Billion USD | 100.029% |
| Halberd Corporation | -74.27 Thousand USD | -1787.22% |
| Enzolytics Inc. | -2.12 Million USD | 33.94% |
| Resverlogix Corp. | -11.74 Million USD | 88.062% |
| Affymax, Inc. | -14.29 Million USD | 90.194% |
| SYBLEU INC | -141.57 Thousand USD | -890.18% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 54.234% |
| argenx SE | -216.02 Million USD | 99.351% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.467% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 215.186% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 6.478% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 470.022% |
| AVAX Technologies, Inc. | -6.11 Million USD | 77.067% |
| Zenith Capital Corp. | -8.6 Million USD | 83.711% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.436% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7946.656% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 42.701% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -696.372% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.463% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 51.534% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -33.976% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 20947.829% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 19.897% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 27.024% |
| BioStem Technologies, Inc. | -7.55 Million USD | 81.442% |
| ONE Bio Corp. | 13.61 Million USD | 110.298% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -674.103% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 31.852% |
| Agentix Corp. | -1.37 Million USD | -2.191% |
| LadRx Corporation | 412.28 Thousand USD | 440.011% |
| Cell Source, Inc. | -4.27 Million USD | 67.19% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -281.734% |
| Regen BioPharma, Inc. | 1.46 Million USD | 195.624% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -49.614% |
| NovAccess Global Inc. | -1.03 Million USD | -35.467% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 115.833% |
| Itoco Inc. | -1.86 Million USD | 24.997% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -269.266% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -25.61% |
| Kadimastem Ltd | -2.62 Million USD | 46.585% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -486.163% |
| CytoDyn Inc. | -18.02 Million USD | 92.225% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1673.789% |
| Mobile Lads Corp. | -2.24 Million USD | 37.452% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -11362.981% |
| Qrons Inc. | -40.08 Thousand USD | -3397.438% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -188.629% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 365.779% |
| Rebus Holdings, Inc. | -951 Thousand USD | -47.404% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -31.996% |
| International Stem Cell Corporation | 202 Thousand USD | 793.964% |
| Bioxytran, Inc. | -3.82 Million USD | 63.305% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2563.009% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 43.061% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.092% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3015.129% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 48.802% |
| Neutra Corp. | -181.24 Thousand USD | -673.424% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 93.046% |
| PureTech Health plc | -11.62 Million USD | 87.944% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 93.046% |
| IXICO plc | -707 Thousand USD | -98.276% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 81.759% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.1% |
| CSL Limited | 4.73 Billion USD | 100.03% |
| Cellectis S.A. | -92.63 Million USD | 98.487% |